Clinical trials: Stroke Acute
Acute Stroke, Endovascular Thrombectomy
Blood Pressure After Endovascular Stroke Therapy-II
The purpose of this study is to assess the safety of lowering blood pressure in acute stroke patients that are successfully treated with a mechanical thrombectomy procedure.
- Trial name
- BEST-II (NCT04116112)
- Testing
- Nicardipine, Labetalol, Hydralazine
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Cincinnati
Stroke, Acute, Cerebral Infarction
Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3
This is a study to evaluate the hypothesis that FDA cleared thrombectomy devices plus medical management leads to superior clinical outcomes in acute ischemic stroke patients at 90 days when compared to medical management alone…
- Trial name
- DEFUSE 3 (NCT02586415)
- Testing
- Endovascular Thrombectomy, Trevo Retriever, Solitaire™ FR Revascularization Device
- Where
- 40 sites in United States
- Volunteers
- 182 people
- Sponsor
- Gregory W Albers
Stroke
Repetitive Transcranial Magnetic Stimulation Use in Acute Stroke
When a certain area of the brain is injured, like in stroke, several events occur. One side of the body may become weak. This weakness is called hemiparesis and it may create difficulty in performing tasks like writing, eating…
- Trial name
- NCT01922986
- Testing
- active rTMS, conventional stroke therapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Minnesota
Stroke, Neurologic Disorder
Evaluation of Bioness Integrated Therapy System (BITS) Touch Screen Technology to Improve Field Awareness
The Bioness Integrated Therapy System (BITS) (Bioness Inc. Valencia, CA) Touch Screen is an FDA approved device comprised of an interactive touchscreen and diverse program options to challenge patients through the use of visual…
- Conditions
- Stroke, Neurologic Disorder, Traumatic Brain Injury, Acquired Brain Injury
- Trial name
- NCT04930822
- Testing
- Table Top Visual Intervention, Bioness Integrated Therapy System Visual Intervention
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Gaylord Hospital, Inc
Stroke, Acute
Solitaire FR Thrombectomy for Acute Revascularisation
The objective of this study was to obtain prospective clinical data on the safety and efficacy of the Solitaire™ FR device for patients diagnosed with acute ischemic stroke.
- Trial name
- STAR (NCT01327989)
- Testing
- Solitaire™ FR device
- Where
- 2 sites in Switzerland
- Volunteers
- 202 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Ischemic Stroke
Assess the Penumbra System in the Treatment of Acute Stroke
The purpose of this trial is to assess the safety and effectiveness of the Penumbra System as an adjunctive treatment to intravenous (IV) recombinant human tissue plasminogen activator (rtPA)in patients with acute ischemic stroke…
- Trial name
- THERAPY (NCT01429350)
- Testing
- intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Penumbra System
- Where
- 4 sites in United States
- Volunteers
- 108 people
- Sponsor
- Penumbra Inc.
Stroke, Acute, Stroke
Functional Electrical Stimulation (FES) for Upper Extremity Recovery in Stroke
Stroke is the leading cause of activity limitation among older adults in the United States. NeuroMuscular Electrical Stimulation (NMES) can assist stroke survivors in regaining motor ability and decreasing activity limitation…
- Conditions
- Stroke, Acute, Stroke, Hemiparesis
- Trial name
- NCT00142792
- Testing
- NMES device with EMG-triggered and Cyclic capabilities
- Where
- 3 sites in United States
- Volunteers
- 122 people
- Sponsor
- MetroHealth Medical Center
Stroke
Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients
The purpose of this study is: To assess the neurological outcome in acute ischemic stroke patients treated with NTx®-265, when compared with patients given a placebo control.
- Trial name
- REGENESIS-LED (NCT00938314)
- Testing
- human chorionic gonadotropin (hCG), then epoetin alfa (EPO)
- Where
- 23 sites in United States, Canada and 1 more
- Volunteers
- 96 people
- Sponsor
- Stem Cell Therapeutics Corp.
Stroke, Acute
Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis
The primary purpose of this study is to determine if a single dose of nerinetide can reduce global disability in people who have had a stroke and are selected for endovascular therapy without the use of a tissue plasminogen…
- Trial name
- ESCAPE-NEXT (NCT04462536)
- Testing
- Nerinetide
- Where
- 81 sites in United States, Australia and 7 more
- Volunteers
- 850 people
- Sponsor
- NoNO Inc.
Stroke, Acute
Efficacy and Safety of Trans Sodium Crocetinate (TSC) for Treatment of Suspected Stroke
This study will assess the potential efficacy and safety of TSC as early treatment for both ischemic and hemorrhagic stroke when administered while subject is in ambulance being transported to hospital.
- Trial name
- PHAST-TSC (NCT03763929)
- Testing
- Trans-Sodium Crocetinate
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Diffusion Pharmaceuticals Inc
Stroke, Acute
Pilot Randomized Controlled Study of the Impact of MedRhythms' MR-010 in Acute Stroke
The purpose of this clinical pilot study is to evaluate the effects of the MR-010 on tolerability, biomechanics and walking speed in the acute stroke care setting in addition to its impact on length of stay.
- Trial name
- NCT04689256
- Testing
- MR-010
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Massachusetts, Worcester
Diabetic Retinopathy, Macular Degeneration
Advancing Understanding of Transportation Options
This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects of a driving decision aid use among geriatric patients and providers.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Glaucoma, Retinitis Pigmentosa
- Trial name
- AUTO (NCT04141891)
- Testing
- Driving Decision Aid, Older Drivers Website
- Where
- 3 sites in United States
- Volunteers
- 529 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Stroke, Ischemic Stroke
Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke
This pilot trial will be the first step toward direct comparison of delivery of endovascular reperfusion therapy to intravenous recombinant tissue plasminogen activator (rt-PA) in a time-to-treatment framework shown as most…
- Trial name
- EARLY (NCT01869478)
- Testing
- Intravenous Thrombolysis, Endovascular Arterial Reperfusion
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Mayo Clinic
Stroke, Ischemic, Inflammatory Response
TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Cohort
DESIGN: exploratory, prospective, natural history, imaging cohort study BACKGROUND: Stroke causes a strong inflammatory response in the brain which is thought to contribute to permanent brain damage in stroke patients.
- Conditions
- Stroke, Ischemic, Inflammatory Response, Stroke, Acute
- Trial name
- NCT03662750
- Testing
- Brain Imaging
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Imperial College London
Ischemic Stroke
Safety of Rt-PA + Transcranial Emission of Low-Energy Lasers for Acute Stroke Recovery
To assess the safety and preliminary efficacy of combining intravenous rt-PA with transcranial laser therapy (TLT) with the NeuroThera® Laser System (referred to hereafter as NTS) in subjects treated for acute ischemic stroke.
- Trial name
- StELLAR (NCT01220739)
- Testing
- Transcranial Laser Therapy
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of California, San Diego
Acute Ischemic Stroke, Diabetes
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial
The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial is a multicenter, randomized, controlled clinical trial of 1400 patients that will include approximately 60 enrolling sites.
- Conditions
- Acute Ischemic Stroke, Diabetes, Hyperglycemia
- Trial name
- SHINE (NCT01369069)
- Testing
- IV insulin to maintain target glucose concentration of 80-130 mg/dL, Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL
- Where
- 70 sites in United States
- Volunteers
- 1,151 people
- Sponsor
- University of Virginia